Strategic leadership Recent board appointments including Carlos Migoya and Don Payerle signal an expanded governance focus and strategic leadership that can accelerate adoption of Curonix’s Freedom PNS System across hospitals and clinics. Sales teams should leverage these hires to open conversations with C-suite and procurement teams about scalable chronic pain solutions.

Product launches Commercial availability of the Freedom PNS System and a next generation wearable accessory indicate ongoing product development and the potential for upsell to existing customers. Target both new clinics and current users for expanded device ecosystems and accessories.

Financial signaling Revenue range of 25 to 50 million dollars and formal CFO appointment suggest growing financial maturity and potential for larger procurement contracts, multi-site deployments, and partnership opportunities with healthcare systems prioritizing opioid-free chronic pain management.

Market focus Specialization in chronic pain relief with a craniofacial focus opens doors to neurology, pain clinics, and multidisciplinary centers. Sales outreach can prioritize integrated care teams and demonstrate long-term cost savings and patient quality-of-life improvements.

Expansion momentum Board additions in 2026 and press coverage across multiple outlets indicate rapid expansion and credibility growth. Use this momentum to approach large healthcare networks, hospital systems, and distributors seeking innovative, evidence-based pain management technologies.